News & Updates

Show Multimedia Only

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

20 Jun 2024 by

Treatment with bulevirtide, either 2 or 10 mg, has shown sustained improvement in virologic and biochemical responses in patients with chronic hepatitis delta (CHD), according to the MYR301 study presented at EASL 2024.

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

20 Jun 2024

Physical activity substantially cuts cirrhosis risk in MASLD patients

19 Jun 2024 by

A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

Physical activity substantially cuts cirrhosis risk in MASLD patients

19 Jun 2024

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

19 Jun 2024 by

Long-term treatment with elafibranor improves biochemical response and itch-related quality of life (QoL) in patients with primary biliary cholangitis (PBC), according to data from the ELATIVE trial presented at EASL 2024.

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

19 Jun 2024

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

18 Jun 2024 by

In a phase IIb open-label trial, combination therapy with bulevirtide and peginterferon alfa-2a (pegIFNα) yields a synergistic on-treatment effect, with more patients achieving undetectable HDV RNA levels compared to bulevirtide alone.

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

18 Jun 2024

MELD 3.0 validated as superior mortality predictor in Asians with cirrhosis

17 Jun 2024 by

The latest update of the model for end-stage liver disease (MELD), MELD 3.0, predicts mortality in multiethnic Asian patients hospitalized with cirrhosis with greater accuracy than previous models, according to a study from Singapore.

MELD 3.0 validated as superior mortality predictor in Asians with cirrhosis

17 Jun 2024

Tirzepatide resolves MASH without worsening fibrosis

11 Jun 2024 by

Treatment with tirzepatide for 52 weeks resulted in MASH* resolution, with no worsening of fibrosis in patients with MASH and fibrosis in the phase II SYNERGY-NASH trial.

Tirzepatide resolves MASH without worsening fibrosis

11 Jun 2024

High-resolution anorectal manometry detects HD in children ≤2 years old

30 May 2024 by

High-resolution anorectal manometry (HR‐ARM) can be a noninvasive primary screening tool for Hirschsprung’s disease (HD), particularly in children ≤2 years old, as shown in a comprehensive retrospective analysis.

High-resolution anorectal manometry detects HD in children ≤2 years old

30 May 2024

48-week data ASSERT odevixibat’s role in ALGS

29 May 2024 by

Pooled analysis of the ASSERT and ASSERT-EXT studies show sustained improvements in multiple parameters with odevixibat in individuals with Alagille syndrome (ALGS), thus reinforcing its role in the treatment of this multisystem genetic disorder.

48-week data ASSERT odevixibat’s role in ALGS

29 May 2024

Maralixibat may benefit certain subgroups of children with PFIC

28 May 2024 by

Maralixibat may have a role in treating a broader profile of children with PFIC, including those who have had biliary diversion surgery and those with MDR3 deficiency, suggest subgroup analyses from the phase III MARCH/MARCH-ON trials

Maralixibat may benefit certain subgroups of children with PFIC

28 May 2024

Prednisone better than anakinra-zinc combo for severe alcohol-associated hepatitis

18 May 2024 by

Use of prednisone in patients with severe alcohol-associated hepatitis (SAH) results in significantly better overall and transplant-free survival at 90 days and a lower incidence of acute kidney injury (AKI) when compared with the use of anakinra plus zinc, results of a study have shown.

Prednisone better than anakinra-zinc combo for severe alcohol-associated hepatitis

18 May 2024

News & Updates

Filter by Specialty:

Specialty:

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

Physical activity substantially cuts cirrhosis risk in MASLD patients

Physical activity substantially cuts cirrhosis risk in MASLD patients

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

MELD 3.0 validated as superior mortality predictor in Asians with cirrhosis

MELD 3.0 validated as superior mortality predictor in Asians with cirrhosis

Tirzepatide resolves MASH without worsening fibrosis

Tirzepatide resolves MASH without worsening fibrosis

High-resolution anorectal manometry detects HD in children ≤2 years old

High-resolution anorectal manometry detects HD in children ≤2 years old

48-week data ASSERT odevixibat’s role in ALGS

48-week data ASSERT odevixibat’s role in ALGS

Maralixibat may benefit certain subgroups of children with PFIC

Maralixibat may benefit certain subgroups of children with PFIC

Prednisone better than anakinra-zinc combo for severe alcohol-associated hepatitis

Prednisone better than anakinra-zinc combo for severe alcohol-associated hepatitis